Tim Ferng, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Avenue, HSE, #740
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Michigan, Ann Arbor, MIBS05/2006Cell and Molecular Biology
    Wayne State University School of Medicine, Detroit, MIMD06/2010Doctor of Medicine
    New York Presbyterian - Weill Cornell Medical Center, New York, NY06/2013Internal Medicine Residency
    University of California San Francisco, San Francisco, CA07/2019Hematology and Oncology Fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Mol Cancer Ther. 2022 05 04; 21(5):844-854. Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. PMID: 35395091; PMCID: PMC9081245.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    2. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 08; 9(8):1050-1063. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. PMID: 31088841.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCells
    3. High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay. J Biomol Screen. 2009 Feb; 14(2):161-72. Evelyn CR, Ferng T, Rojas RJ, Larsen MJ, Sondek J, Neubig RR. PMID: 19196702; PMCID: PMC2698131.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    Tim's Networks
    Concepts (37)
    Derived automatically from this person's publications.
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _